As of May 2025, RGX-202 displayed favourable safety, with no serious adverse events (SAEs) and adverse events of special ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the AFFINITY DUCHENNE® pivotal trial of RGX-202, an investigational gene therapy for the treatment of Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback